173 related articles for article (PubMed ID: 30365110)
21. Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.
Peled A; Klein S; Beider K; Burger JA; Abraham M
Cytokine; 2018 Sep; 109():11-16. PubMed ID: 29903571
[TBL] [Abstract][Full Text] [Related]
22. The chemokine X-factor: Structure-function analysis of the CXC motif at CXCR4 and ACKR3.
Wedemeyer MJ; Mahn SA; Getschman AE; Crawford KS; Peterson FC; Marchese A; McCorvy JD; Volkman BF
J Biol Chem; 2020 Oct; 295(40):13927-13939. PubMed ID: 32788219
[TBL] [Abstract][Full Text] [Related]
23. ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.
Chen Z; Teo AE; McCarty N
Clin Cancer Res; 2016 Jan; 22(1):187-99. PubMed ID: 26350264
[TBL] [Abstract][Full Text] [Related]
24. CXCL12/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukemia and oroxylin A improves the sensitivity of K562/ADM cells.
Wang Y; Miao H; Li W; Yao J; Sun Y; Li Z; Zhao L; Guo Q
Biochem Pharmacol; 2014 Aug; 90(3):212-25. PubMed ID: 24858801
[TBL] [Abstract][Full Text] [Related]
25. Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside.
Cho BS; Kim HJ; Konopleva M
Korean J Intern Med; 2017 Mar; 32(2):248-257. PubMed ID: 28219003
[TBL] [Abstract][Full Text] [Related]
26. Dual-action CXCR4-targeting liposomes in leukemia: function blocking and drug delivery.
McCallion C; Peters AD; Booth A; Rees-Unwin K; Adams J; Rahi R; Pluen A; Hutchinson CV; Webb SJ; Burthem J
Blood Adv; 2019 Jul; 3(14):2069-2081. PubMed ID: 31292126
[TBL] [Abstract][Full Text] [Related]
27. Fragment-based optimization of small molecule CXCL12 inhibitors for antagonizing the CXCL12/CXCR4 interaction.
Ziarek JJ; Liu Y; Smith E; Zhang G; Peterson FC; Chen J; Yu Y; Chen Y; Volkman BF; Li R
Curr Top Med Chem; 2012; 12(24):2727-40. PubMed ID: 23368099
[TBL] [Abstract][Full Text] [Related]
28. The CXCR4-SDF1alpha axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma.
Strahm B; Durbin AD; Sexsmith E; Malkin D
Clin Exp Metastasis; 2008; 25(1):1-10. PubMed ID: 17768666
[TBL] [Abstract][Full Text] [Related]
29. A designed peptide targeting CXCR4 displays anti-acute myelocytic leukemia activity in vitro and in vivo.
Li X; Guo H; Yang Y; Meng J; Liu J; Wang C; Xu H
Sci Rep; 2014 Oct; 4():6610. PubMed ID: 25312253
[TBL] [Abstract][Full Text] [Related]
30. Transplantation of RADA16-BDNF peptide scaffold with human umbilical cord mesenchymal stem cells forced with CXCR4 and activated astrocytes for repair of traumatic brain injury.
Shi W; Huang CJ; Xu XD; Jin GH; Huang RQ; Huang JF; Chen YN; Ju SQ; Wang Y; Shi YW; Qin JB; Zhang YQ; Liu QQ; Wang XB; Zhang XH; Chen J
Acta Biomater; 2016 Nov; 45():247-261. PubMed ID: 27592818
[TBL] [Abstract][Full Text] [Related]
31. Role of CXCL12/CXCR4 signaling axis in pancreatic cancer.
Wu PF; Lu ZP; Cai BB; Tian L; Zou C; Jiang KR; Miao Y
Chin Med J (Engl); 2013; 126(17):3371-4. PubMed ID: 24033967
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, and biological evaluation of CXCR4 ligands.
Mona CE; Besserer-Offroy É; Cabana J; Leduc R; Lavigne P; Heveker N; Marsault É; Escher E
Org Biomol Chem; 2016 Nov; 14(43):10298-10311. PubMed ID: 27752700
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia.
Liu P; Ma D; Yu Z; Zhe N; Ren M; Wang P; Yu M; Huang J; Fang Q; Wang J
Biomed Pharmacother; 2017 Jul; 91():21-30. PubMed ID: 28445830
[TBL] [Abstract][Full Text] [Related]
34. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.
Sison EA; McIntyre E; Magoon D; Brown P
Mol Cancer Res; 2013 Sep; 11(9):1004-16. PubMed ID: 23754844
[TBL] [Abstract][Full Text] [Related]
35. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia.
Chen Y; Jacamo R; Konopleva M; Garzon R; Croce C; Andreeff M
J Clin Invest; 2013 Jun; 123(6):2395-407. PubMed ID: 23676502
[TBL] [Abstract][Full Text] [Related]
36. CXCL14 is a natural inhibitor of the CXCL12-CXCR4 signaling axis.
Tanegashima K; Suzuki K; Nakayama Y; Tsuji K; Shigenaga A; Otaka A; Hara T
FEBS Lett; 2013 Jun; 587(12):1731-5. PubMed ID: 23669361
[TBL] [Abstract][Full Text] [Related]
37. CXCL14 antagonizes the CXCL12-CXCR4 signaling axis.
Hara T; Tanegashima K
Biomol Concepts; 2014 May; 5(2):167-73. PubMed ID: 25372750
[TBL] [Abstract][Full Text] [Related]
38. Survival and Proliferation of Neural Progenitor-Derived Glioblastomas Under Hypoxic Stress is Controlled by a CXCL12/CXCR4 Autocrine-Positive Feedback Mechanism.
Calinescu AA; Yadav VN; Carballo E; Kadiyala P; Tran D; Zamler DB; Doherty R; Srikanth M; Lowenstein PR; Castro MG
Clin Cancer Res; 2017 Mar; 23(5):1250-1262. PubMed ID: 27542769
[No Abstract] [Full Text] [Related]
39. Altered CXCL12 expression reveals a dual role of CXCR4 in osteosarcoma primary tumor growth and metastasis.
Neklyudova O; Arlt MJ; Brennecke P; Thelen M; Gvozdenovic A; Kuzmanov A; Robl B; Botter SM; Born W; Fuchs B
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1739-50. PubMed ID: 27300512
[TBL] [Abstract][Full Text] [Related]
40. The CXCL12/CXCR4 axis as a therapeutic target in cancer and HIV-1 infection.
Patrussi L; Baldari CT
Curr Med Chem; 2011; 18(4):497-512. PubMed ID: 21143114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
